Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Success rates vary by agency, topic, and phase, but most agencies fund somewhere between 10% and 25% of Phase I proposals
Do you need it
Key Research Findings Published research indicates BPC 157 may influence several biological processes
Wolverine Blend (BPC-157 + TB-500) is investigational and supplied for in-vitro research, not human consumption
A: Yesin fact, peptides often work better when combined with optimized hormone levels
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
US$ 22.94
US$ 22.16
US$ 27.15
US$ 24.43
US$ 24.15
